Significant developments have occurred in the field of pulmonary hypertension (PH) in the past 2 years, especially in terms of treatment options available. These include: approval of new drugs; evidence for use of initial combination therapies in pulmonary arterial hypertension; approved drugs for use in chronic thromboembolic disease not amenable to, or persistent after surgical thromboendarterectomy; and ongoing clinical trials in PH related to left heart disease and hypoxia. The field continues to evolve and address the challenges in treatment of this multifaceted disease with the aim to provide novel solutions and meet the needs of a growing population with PH. This has led to an extensive body of literature, ranging from case series to prospective, multicenter clinical trials, which will enhance the future of patient outcomes in PH. This contemporary review highlights the key articles in treatment updates for PH for the years 2013 to 2015.
|Original language||English (US)|
|Number of pages||9|
|Journal||Journal of Heart and Lung Transplantation|
|State||Published - Jun 1 2016|
Bibliographical noteFunding Information:
M.K.K. has received a speaker’s fee from Bayer Pharma. J.L.V. received consultancy and speaker’s fees from Actelion Pharmaceuticals and GlaxoSmithKline, and speaker’s fees from Bayer Pharma and travel grants from Bayer Pharma and United Therapeutics.
© 2016 International Society for Heart and Lung Transplantation. All rights reserved.
- clinical trials
- pulmonary hypertension
- pulmonary vascular disease